SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Lobe Sciences Ltd. (LOBEF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 39/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LOBEF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.03
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.24 |
$0.00 |
$-55.97K |
- |
| 2017 |
$-0.08 |
$0.00 |
$-51.8K |
- |
| 2018 |
$-0.24 |
$0.00 |
$-148K |
- |
| 2019 |
$-0.09 |
$773.79K |
$-754K |
-97.4% |
| 2020 |
$-0.30 |
$884.84K |
$-3.44M |
-388.3% |
| 2021 |
$-0.30 |
$0.00 |
$-9.66M |
- |
| 2022 |
$-0.32 |
$0.00 |
$-12.25M |
- |
| 2023 |
$-0.05 |
$840.53K |
$-4.71M |
-560% |
| 2024 |
$-0.03 |
$136.21K |
$-4.42M |
-3245.8% |
| 2025 |
$-0.03 |
$0.00 |
$-4.42M |
- |
